Daniel Ketelhuth

Professor of Cardiovascular Pharmacology

University of Southern Denmark

Denmark

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Daniel Ketelhuth is a faculty member at the University of Southern Denmark, specializing in Cardiovascular Pharmacology. His research areas include the modulation of immune responses in cardiovascular diseases, the impact of metabolic pathways on atherosclerosis, and innovations in cardiovascular prevention and treatment. Recent articles by Professor Ketelhuth focus on the role of pyruvate dehydrogenase in inflammatory responses and the implications of interleukin-6 in novel therapeutic approaches.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (11)

Mulugeta Melkie Zegeye

University of Oxford

UNITED KINGDOM

View details

Liza Ljungberg

Associate Professor

Örebro universitet Institutionen för medicinska vetenskaper

SWEDEN

View details

Goran Hansson

Karolinska Institutet

SWEDEN

View details

Felipe Casagrande

Karolinska University Hospital

SWEDEN

View details

Hong Jin

Karolinska Institutet

SWEDEN

View details

Maria Josefa Forteza

Karolinska Institutet

SWEDEN

View details

Jacob Odeberg

KTH Royal Institute of Technology

SWEDEN

View details

Giuseppe Danilo Norata

University of Milan

ITALY

View details

Jane Stubbe

aoosicate professor

University of Southern Denmark

DENMARK

View details

Anton Gisterå

Karolinska Institutet

SWEDEN

View details

Ashok Kumar Kumawat

Senior Lecturer, Associate professor in Biomedicine

Örebro university

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Daniel Ketelhuth

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Targeting the pyruvate dehydrogenase kinase/pyruvate dehydrogenase axis modulates neutrophil and smooth muscle cell pathological responses and prevents abdominal aortic aneurysm formation

Fgf23 expression increases atherosclerotic plaque burden in male ApoE deficient mice

Intervention, improved prevention, imaging, inflammation, and innovation: the five I's cardiovascular highlights in <i>EHJ Open </i>2024

PCSK6 ablation in blood circulating cells increases atherosclerotic burden, but improves plaque stability by activating Th17-smooth muscle cell modulatory axis

Roadmap for alleviating the manifestations of ageing in the cardiovascular system

Understanding immunometabolism in cardiovascular disease: translating research into practice

Understanding immunometabolism in cardiovascular disease: translating research into practice

Myeloid-specific interleukin-6 response: from vascular effects to the potential for novel personalized medicines

Editors' highlight picks from 2023 in EHJ Open

Cystathionine gamma-lyase (CTH) inhibition attenuates glioblastoma formation

Animal Models of Atherosclerosis–Supportive Notes and Tricks of the Trade

Genetic Deficiency of Indoleamine 2,3-dioxygenase Aggravates Vascular but Not Liver Disease in a Nonalcoholic Steatohepatitis and Atherosclerosis Comorbidity Model

Inhibition of IL17A Using an Affibody Molecule Attenuates Inflammation in ApoE-Deficient Mice

Metabolism in atherosclerotic plaques: immunoregulatory mechanisms in the arterial wall

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease.

Animal Models of Atherosclerosis–Supportive Notes and Tricks of the Trade

ApoB100‐reactive T cells: Does liver tolerance hold the key to modulating adaptive immunity in atherosclerosis?

The resolvin D1 receptor GPR32 transduces inflammation resolution and atheroprotection

The mineralocorticoid receptor blocker spironolactone lowers plasma interferon-γ and interleukin-6 in patients with type 2 diabetes and treatment-resistant hypertension

Open Up your Science in EHJ Open

Collaborators (11)

Mulugeta Melkie Zegeye

Liza Ljungberg

Goran Hansson

Felipe Casagrande

Hong Jin

Maria Josefa Forteza

Jacob Odeberg

Giuseppe Danilo Norata

Jane Stubbe

Anton Gisterå

Ashok Kumar Kumawat

Make your next move.